---
title: "Silexion Therapeutics Announces 1-for-10 Reverse Share Split"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288785467.md"
description: "On May 29, 2026, trading for Silexion will commence on a split-adjusted basis at the market open. This strategic adjustment aims to assist Silexion in meeting Nasdaq requirements and bolstering its market standing. The move will support the company's advancement in developing SIL204, showcasing its commitment to growth and compliance."
datetime: "2026-06-04T23:57:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288785467.md)
  - [en](https://longbridge.com/en/news/288785467.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288785467.md)
---

# Silexion Therapeutics Announces 1-for-10 Reverse Share Split

On May 29, 2026, trading for Silexion will commence on a split-adjusted basis at the market open. This strategic adjustment aims to assist Silexion in meeting Nasdaq requirements and bolstering its market standing. The move will support the company's advancement in developing SIL204, showcasing its commitment to growth and compliance.

### Related Stocks

- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)

## Related News & Research

- [Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer | SLXN Stock News](https://longbridge.com/en/news/286425411.md)
- [Vivos Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard](https://longbridge.com/en/news/289056666.md)
- [Parvinder Singh Hyare Backs Obsidian Deal at Galera Therapeutics with 6.65% Stake](https://longbridge.com/en/news/289517633.md)
- [Is Sarepta Therapeutics (SRPT) Quietly Rewriting Its Risk Profile With New Equity Plans And Q1 Profitability?](https://longbridge.com/en/news/289030593.md)
- [Ovid Therapeutics Shareholders Back Board and Governance Proposals](https://longbridge.com/en/news/289477648.md)